A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer

NCT06492005 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple-Negative Breast Cancer

Interventions

DRUG: 9MW2821
DRUG: PD-1 inhibitior

Sponsor

Mabwell (Shanghai) Bioscience Co., Ltd.